Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) EBT (2018 - 2025)

X4 Pharmaceuticals' EBT history spans 8 years, with the latest figure at -$23.9 million for Q4 2025.

  • For Q4 2025, EBT rose 39.53% year-over-year to -$23.9 million; the TTM value through Dec 2025 reached -$79.2 million, down 113.13%, while the annual FY2025 figure was -$79.2 million, 113.13% down from the prior year.
  • EBT reached -$23.9 million in Q4 2025 per XFOR's latest filing, up from -$29.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $90.9 million in Q2 2024 to a low of -$55.7 million in Q2 2023.
  • Average EBT over 5 years is -$20.0 million, with a median of -$22.9 million recorded in 2022.
  • The largest YoY upside for EBT was 263.12% in 2024 against a maximum downside of 1509.52% in 2024.
  • A 5-year view of EBT shows it stood at -$30.2 million in 2021, then grew by 3.69% to -$29.1 million in 2022, then skyrocketed by 34.35% to -$19.1 million in 2023, then tumbled by 107.17% to -$39.6 million in 2024, then skyrocketed by 39.53% to -$23.9 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's EBT are -$23.9 million (Q4 2025), -$29.8 million (Q3 2025), and -$25.7 million (Q2 2025).